The development and value-creation of early-stage biotech companies is often hampered by the lack of access to two key resources: 1) Venture capital and 2) State-of-the-art technology platforms to validate and advance therapeutic candidates. At Evotec, we are aiming to lower both barriers through our approach with Evotec Venturing by 1) Strategically investing into promising early-stage biotech companies (Equity) and 2) Creating and supporting pre-seed incubators with top-tier academic institutions (BRIDGES).